# SRD5A1

## Overview
The SRD5A1 gene encodes the enzyme steroid 5 alpha-reductase 1, a critical component in the steroid metabolism pathway. This enzyme is responsible for the conversion of testosterone into dihydrotestosterone (DHT), a more potent androgen, and is categorized as an oxidoreductase. Steroid 5 alpha-reductase 1 is active in various tissues, including the liver and skin, and plays a significant role in physiological processes such as sexual differentiation, prostate development, and hair growth. The enzyme's activity is also linked to adipocyte differentiation and metabolism, with implications for body mass index (BMI) and adipose tissue function (Fouad2016Characterization). Furthermore, SRD5A1 interacts with several proteins involved in androgen metabolism, suggesting its involvement in modulating therapy response and disease progression, particularly in prostate cancer (Bamodu2021Differential). The gene's clinical significance is underscored by its association with metabolic disorders and its potential as a therapeutic target in oncological contexts (Liu2020Associations).

## Function
SRD5A1 encodes the enzyme steroid 5 alpha-reductase 1, which plays a crucial role in the conversion of testosterone to dihydrotestosterone (DHT), a more potent androgen. This enzyme is involved in the metabolism of steroids and is active in various tissues, including the liver and skin. In human abdominal adipose tissues, SRD5A1 is expressed in both omental and subcutaneous adipose tissues, although its expression is lower than that of SRD5A3 (Fouad2016Characterization). The enzyme is involved in the synthesis of DHT from androstenedione (4-dione), which is a significant source of DHT in preadipocytes (Fouad2016Characterization).

The activity of SRD5A1 is linked to the regulation of adipocyte differentiation and metabolism. Inhibition of 5α-reductase activity, including that of SRD5A1, can abolish the differentiation of preadipocytes, as measured by glycerol-3-phosphate dehydrogenase (G3PDH) activity (Fouad2016Characterization). Additionally, SRD5A1 expression in subcutaneous adipose tissue correlates positively with body mass index (BMI), suggesting a role in adipose tissue function and possibly in the regulation of adipocyte differentiation (Fouad2016Characterization). The enzyme's activity in converting testosterone to DHT is essential for various physiological processes, including sexual differentiation, prostate development, and hair growth.

## Clinical Significance
Mutations and alterations in the expression of the SRD5A1 gene have been implicated in various diseases and conditions. In the context of metabolic disorders, the SRD5A1 gene variant rs1691053 has been associated with impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM) in males. Males with the CC genotype of this polymorphism exhibit higher fasting plasma glucose and glycosylated hemoglobin levels, indicating a potential risk factor for dysglycemia (Liu2020Associations).

In prostate cancer, SRD5A1 is significantly upregulated, particularly in high-grade tumors and castration-resistant prostate cancer (CRPC). This upregulation is linked to tumor progression, poor prognosis, and therapy resistance. The gene's role in converting testosterone to dihydrotestosterone (DHT) contributes to the aggressive nature of prostate cancer and its resistance to traditional androgen deprivation therapies. Targeting SRD5A1 with inhibitors like Dutasteride and Finasteride has shown potential in enhancing treatment efficacy and reducing tumor burden (Bamodu2021Differential).

These findings underscore the clinical significance of SRD5A1 in both metabolic and oncological contexts, highlighting its potential as a therapeutic target.

## Interactions
The SRD5A1 gene encodes the enzyme steroid 5 alpha-reductase 1, which is involved in steroid metabolism and has significant interactions with other proteins. SRD5A1 is part of a protein complex that includes sex hormone-binding globulin (SHBG), hydroxysteroid 17-beta dehydrogenase 2 (HSD17B2), and hydroxysteroid 17-beta dehydrogenase 3 (HSD17B3). This complex is implicated in androgenic signaling and testosterone metabolism, playing a crucial role in transcriptional regulation (Bamodu2021Differential). Molecular docking studies have shown that SRD5A1 forms a macro-complex with HSD17B2, HSD17B3, and SHBG, which may influence the recurrent phenotype in prostate cancer patients (Bamodu2021Differential).

SRD5A1 also interacts with cytochrome P450 family 17 subfamily A member 1 (CYP17A1), further contributing to its role in androgen metabolism (Bamodu2021Differential). The interactions of SRD5A1 with these proteins suggest its involvement in modulating therapy response and disease progression in prostate cancer, particularly in castration-resistant prostate cancer (CRPC) (Bamodu2021Differential). These interactions highlight the potential of targeting SRD5A1 as a therapeutic strategy to counteract androgen-driven oncogenic signals and treatment resistance in prostate cancer (Bamodu2021Differential).


## References


[1. (Fouad2016Characterization) Mohamed Fouad Mansour, Mélissa Pelletier, and André Tchernof. Characterization of 5α-reductase activity and isoenzymes in human abdominal adipose tissues. The Journal of Steroid Biochemistry and Molecular Biology, 161:45–53, July 2016. URL: http://dx.doi.org/10.1016/j.jsbmb.2016.02.003, doi:10.1016/j.jsbmb.2016.02.003. This article has 17 citations.](https://doi.org/10.1016/j.jsbmb.2016.02.003)

[2. (Bamodu2021Differential) Oluwaseun Adebayo Bamodu, Kai-Yi Tzou, Chia-Da Lin, Su-Wei Hu, Yuan-Hung Wang, Wen-Ling Wu, Kuan-Chou Chen, and Chia-Chang Wu. Differential but concerted expression of hsd17b2, hsd17b3, shbg and srd5a1 testosterone tetrad modulate therapy response and susceptibility to disease relapse in patients with prostate cancer. Cancers, 13(14):3478, July 2021. URL: http://dx.doi.org/10.3390/cancers13143478, doi:10.3390/cancers13143478. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13143478)

[3. (Liu2020Associations) Xue Liu, Dandan Wei, Jingjing Jiang, Xiaotian Liu, Runqi Tu, Zhicheng Luo, Yan Wang, Xiaokang Dong, Dou Qiao, Fang Shen, Ruiying Li, Yikang Wang, Yuxi Jin, Songcheng Yu, Wenqian Huo, Linlin Li, Wenjie Li, Tao Jing, Chongjian Wang, and Zhenxing Mao. Associations of srd5a1 gene variants and testosterone with dysglycemia: henan rural cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 30(4):599–607, April 2020. URL: http://dx.doi.org/10.1016/j.numecd.2019.11.011, doi:10.1016/j.numecd.2019.11.011. This article has 2 citations.](https://doi.org/10.1016/j.numecd.2019.11.011)